


Toxicological Profile for Molybdenum

May 2020



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

CS274127-A

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
May 2020	Final toxicological profile released
April 2017	Draft for public comment toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

G. Daniel Todd, Ph.D. (Lead)
Sam Keith, M.S., C.H.P.
Obaid Faroon, D.V.M., Ph.D.
Melanie Buser, M.P.H.

Lisa Ingerman, Ph.D., D.A.B.T.
Mario Citra, Ph.D.
Gary L. Diamond, Ph.D.
Courtney Hard, B.A.
Julie M. Klotzbach, Ph.D.
Amy Nguyen, Ph.D.

ATSDR, Division of Toxicology and Human Health
Sciences, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Division of Community Health Investigations; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA, Office of Water.

PEER REVIEWERS

1. David C. Dorman, DVM, Ph.D., DABT, DABVT, Professor, Toxicology, North Carolina State University, Raleigh, North Carolina
2. Jonathan H Freedman, Ph.D., Professor, Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky
3. Michael Aschner, Ph.D., Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York
4. John Meeker, Sc.D., C.I.H., Professor, Environmental Health Sciences, Associate Dean for Research, School of Public Health, University of Michigan, Ann Arbor, Michigan
5. Alexander V. Lyubimov, M.D., Ph.D., D.A.B.T., Toxicology Research Laboratory, Chicago, Illinois
6. Dagobert Heijerick, ARCHE consulting, Gent, Belgium

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS.....	vi
CONTENTS	vii
LIST OF FIGURES.....	ix
LIST OF TABLES	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH.....	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS.....	2
1.3 MINIMAL RISK LEVELS (MRLs).....	4
CHAPTER 2. HEALTH EFFECTS	6
2.1 INTRODUCTION.....	6
2.2 DEATH.....	33
2.3 BODY WEIGHT.....	33
2.4 RESPIRATORY	35
2.5 CARDIOVASCULAR.....	37
2.6 GASTROINTESTINAL.....	37
2.7 HEMATOLOGICAL	38
2.8 MUSCULOSKELETAL	39
2.9 HEPATIC	41
2.10 RENAL.....	42
2.11 DERMAL	44
2.12 OCULAR.....	44
2.13 ENDOCRINE	45
2.14 IMMUNOLOGICAL	46
2.15 NEUROLOGICAL.....	46
2.16 REPRODUCTIVE	47
2.17 DEVELOPMENTAL.....	50
2.18 OTHER NONCANCER.....	51
2.19 CANCER.....	53
2.20 GENOTOXICITY	54
2.21 MECHANISMS OF ACTION.....	58
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	61
3.1 TOXICOKINETICS.....	61
3.1.1 Absorption.....	61
3.1.2 Distribution	64
3.1.3 Metabolism	66
3.1.4 Excretion.....	66
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models.....	68
3.1.6 Animal-to-Human Extrapolations	72

3.2	CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	72
3.3	BIOMARKERS OF EXPOSURE AND EFFECT	74
3.3.1	Biomarkers of Exposure	75
3.3.2	Biomarkers of Effect	75
3.4	INTERACTIONS WITH OTHER CHEMICALS	75
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		77
4.1	CHEMICAL IDENTITY	77
4.2	PHYSICAL AND CHEMICAL PROPERTIES	79
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE		83
5.1	OVERVIEW	83
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	85
5.2.1	Production	85
5.2.2	Import/Export	88
5.2.3	Use	89
5.2.4	Disposal	90
5.3	RELEASES TO THE ENVIRONMENT	90
5.3.1	Air	91
5.3.2	Water	93
5.3.3	Soil	94
5.4	ENVIRONMENTAL FATE	94
5.4.1	Transport and Partitioning	94
5.4.2	Transformation and Degradation	96
5.5	LEVELS IN THE ENVIRONMENT	97
5.5.1	Air	98
5.5.2	Water	100
5.5.3	Sediment and Soil	103
5.5.4	Other Media	104
5.6	GENERAL POPULATION EXPOSURE	104
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	112
CHAPTER 6. ADEQUACY OF THE DATABASE		113
6.1	INFORMATION ON HEALTH EFFECTS	113
6.2	IDENTIFICATION OF DATA NEEDS	113
6.3	ONGOING STUDIES	121
CHAPTER 7. REGULATIONS AND GUIDELINES		122
CHAPTER 8. REFERENCES		125
APPENDICES		
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS		A-1
APPENDIX B. LITERATURE REVIEW SEARCH FRAMEWORK FOR MOLYBDENUM		B-1
APPENDIX C. FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR MOLYBDENUM		C-1
APPENDIX D. USER'S GUIDE		D-1
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS		E-1
APPENDIX F. GLOSSARY		F-1
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS		G-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Oral Exposure to Molybdenum.....	3
1-2. Summary of Sensitive Targets of Molybdenum – Oral	5
2-1. Overview of the Number of Studies Examining Molybdenum Health Effects.....	11
2-2. Levels of Significant Exposure to Molybdenum – Inhalation	16
2-3. Levels of Significant Exposure to Molybdenum – Oral	26
3-1. The Proposed Systemic Model for Molybdenum Radionuclides.....	69
3-2. Diagram of the Compartment Molybdenum Model	71
5-1. Number of NPL Sites with Molybdenum Contamination	83
6-1. Summary of Existing Health Effects Studies on Molybdenum By Route and Endpoint.....	114

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Molybdenum	5
2-1. Levels of Significant Exposure to Molybdenum – Inhalation	12
2-2. Levels of Significant Exposure to Molybdenum – Oral	19
2-3. Levels of Significant Exposure to Molybdenum – Dermal	30
2-4. Genotoxicity of Molybdenum Compounds <i>In Vivo</i>	55
2-5. Genotoxicity of Molybdenum Compounds <i>In Vitro</i>	55
3-1. Transfer Rates (Day ⁻¹) for the Molybdenum Model.....	69
4-1. Chemical Identity of Molybdenum and Compounds.....	78
4-2. Physical and Chemical Properties of Molybdenum and Compounds.....	80
5-1. Facilities that Produce, Process, or Use Molybdenum Trioxide	86
5-2. Molybdenum U.S. Production, Import, and Export Data from 2010 to 2014 and 2018 in Metric Tons.....	88
5-3. Releases to the Environment from Facilities that Produce, Process, or Use Molybdenum Trioxide	91
5-4. Lowest Limit of Detection Based on Standards.....	97
5-5. Summary of Environmental Levels of Molybdenum	98
5-6. Molybdenum Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	98
5-7. 24-Hour Molybdenum Concentrations (µg/m ³) in Air Samples (2018 Data).....	99
5-8. Molybdenum Levels Detected in Foods in the 2006–2011 and 2013–2014 Market Basket Surveys	105
5-9. Urinary Molybdenum Levels in U.S. Adults	106
5-10. Molybdenum Levels in Breast Milk in Mothers of Term and Preterm Infants.....	109
5-11. Urinary Molybdenum Levels in U.S. Children and Adolescents	110
7-1. Regulations and Guidelines Applicable to Molybdenum	122